Agios Pharmaceuticals (AGIO) News Today → After Conviction, More Bad News for Trump (From Paradigm Press) (Ad) Free AGIO Stock Alerts $47.61 -0.19 (-0.40%) (As of 06/7/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 7 at 5:35 AM | marketbeat.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Acquired by Allianz Asset Management GmbHAllianz Asset Management GmbH boosted its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 38.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 149,111 shares of the biopharmaceutical company's stock after acquiring an addiJune 7 at 2:32 AM | americanbankingnews.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Forecasted to Post FY2027 Earnings of ($3.21) Per ShareJune 6 at 8:00 AM | marketbeat.comBrokers Offer Predictions for Agios Pharmaceuticals, Inc.'s FY2027 Earnings (NASDAQ:AGIO)Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Equities research analysts at Leerink Partnrs issued their FY2027 earnings estimates for Agios Pharmaceuticals in a report issued on Monday, June 3rd. Leerink Partnrs analyst A. Berens anticipates that the biopharmaceutical company will poJune 6 at 6:27 AM | marketbeat.comCampbell & CO Investment Adviser LLC Buys New Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Campbell & CO Investment Adviser LLC purchased a new position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 42,686 shares of the biopharmJune 6 at 3:06 AM | americanbankingnews.comAgios Pharmaceuticals (NASDAQ:AGIO) Given New $53.00 Price Target at Royal Bank of CanadaJune 6 at 1:26 AM | americanbankingnews.comAgios Pharmaceuticals (NASDAQ:AGIO) Stock Price Up 3.1% Following Analyst UpgradeJune 5 at 11:53 AM | marketbeat.comArmistice Capital LLC Acquires 200,000 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Armistice Capital LLC boosted its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 6.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,524,000 shares ofJune 5 at 4:52 AM | americanbankingnews.comThe Goldman Sachs Group Raises Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $53.00June 5 at 3:16 AM | americanbankingnews.comAgios Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:AGIO)June 4, 2024 | marketbeat.comAgios Pharmaceuticals (NASDAQ:AGIO) PT Raised to $53.00The Goldman Sachs Group increased their price target on shares of Agios Pharmaceuticals from $33.00 to $53.00 and gave the company a "neutral" rating in a research note on Tuesday.June 4, 2024 | marketbeat.comAgios Pharmaceuticals (NASDAQ:AGIO) Stock Price Up 3.1% After Analyst UpgradeAgios Pharmaceuticals (NASDAQ:AGIO) Trading Up 3.1% on Analyst UpgradeJune 4, 2024 | americanbankingnews.comShort Interest in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Declines By 6.6%June 3, 2024 | marketbeat.comAgios Pharmaceuticals (NASDAQ:AGIO) Reaches New 12-Month High at $41.74Agios Pharmaceuticals (NASDAQ:AGIO) Hits New 12-Month High at $41.74June 3, 2024 | marketbeat.comAgios Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:AGIO)Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) saw unusually large options trading activity on Monday. Stock investors bought 3,284 put options on the company. This is an increase of 1,077% compared to the average volume of 279 put options.June 3, 2024 | reuters.comAgios Pharmaceuticals' blood disorder drug succeeds in late-stage studyJune 3, 2024 | globenewswire.comAgios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-ThalassemiaJune 3, 2024 | americanbankingnews.comZacks Research Weighs in on Agios Pharmaceuticals, Inc.'s Q3 2025 Earnings (NASDAQ:AGIO)June 2, 2024 | marketbeat.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest UpdateAgios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) saw a significant drop in short interest in the month of May. As of May 15th, there was short interest totalling 6,080,000 shares, a drop of 6.6% from the April 30th total of 6,510,000 shares. Based on an average daily volume of 717,300 shares, the short-interest ratio is currently 8.5 days. Approximately 11.0% of the company's stock are short sold.June 2, 2024 | americanbankingnews.comAgios Pharmaceuticals, Inc. Forecasted to Earn Q4 2024 Earnings of ($1.68) Per Share (NASDAQ:AGIO)May 31, 2024 | marketbeat.comLeerink Partnrs Comments on Agios Pharmaceuticals, Inc.'s Q4 2024 Earnings (NASDAQ:AGIO)Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Research analysts at Leerink Partnrs decreased their Q4 2024 earnings per share (EPS) estimates for shares of Agios Pharmaceuticals in a note issued to investors on Tuesday, May 28th. Leerink Partnrs analyst A. Berens now anticipates thatMay 30, 2024 | globenewswire.comAgios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024May 30, 2024 | americanbankingnews.comAgios Pharmaceuticals (NASDAQ:AGIO) Sets New 52-Week High at $39.70May 30, 2024 | americanbankingnews.comAgios Pharmaceuticals (NASDAQ:AGIO) Upgraded to Hold at StockNews.comMay 29, 2024 | marketbeat.comTrexquant Investment LP Acquires Shares of 54,541 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Trexquant Investment LP bought a new position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 54,541 shares of the biopharmaceutical companMay 29, 2024 | marketbeat.comAgios Pharmaceuticals (NASDAQ:AGIO) Stock Rating Upgraded by StockNews.comStockNews.com raised Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Wednesday.May 28, 2024 | msn.comRoyalty Pharma Flat on Buying into AgiosMay 28, 2024 | finance.yahoo.comAgios cashes in on cancer drug again with $905M Royalty Pharma dealMay 28, 2024 | msn.comAgios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break OutMay 28, 2024 | finance.yahoo.comAgios Breaks Out On 'Buffed Up' Financials After Inking Massive Brain Cancer DealMay 28, 2024 | marketbeat.comAgios Pharmaceuticals (NASDAQ:AGIO) Hits New 1-Year High at $39.70Agios Pharmaceuticals (NASDAQ:AGIO) Hits New 12-Month High at $39.70May 28, 2024 | finanznachrichten.deRoyalty Pharma plc: Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 MillionMay 28, 2024 | markets.businessinsider.comAgios Pharma Stock Climbs On Royalty Pharma's Deal To Buy Royalty Stake In VorasidenibMay 28, 2024 | msn.comAgios in pact with Royalty Pharma for brain tumor candidateMay 28, 2024 | finance.yahoo.comAgios Announces $905 Million Purchase Agreement for Vorasidenib RoyaltyMay 28, 2024 | marketbeat.comDimensional Fund Advisors LP Purchases 137,873 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Dimensional Fund Advisors LP boosted its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 5.6% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 2,596,764 shares of the biopharmaceutical company's stock after purchasingMay 23, 2024 | marketbeat.comBNP Paribas Financial Markets Acquires 66,070 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)BNP Paribas Financial Markets grew its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 111.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 125,309 shares of the biopharmaceutical company's stock aftMay 22, 2024 | marketbeat.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Forecasted to Post Q2 2024 Earnings of ($1.59) Per ShareAgios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Stock analysts at Zacks Research upped their Q2 2024 earnings estimates for Agios Pharmaceuticals in a research note issued on Monday, May 20th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will postMay 14, 2024 | markets.businessinsider.comRBC Capital Reaffirms Their Hold Rating on Inovio Pharmaceuticals (INO)May 14, 2024 | globenewswire.comAgios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid CongressMay 6, 2024 | finance.yahoo.comAgios to Present at the BofA Securities 2024 Health Care Conference on May 16, 2024May 6, 2024 | marketbeat.comFisher Asset Management LLC Sells 106,543 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Fisher Asset Management LLC trimmed its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 13.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 710,876 shares of the biopharmaceutical company's stockMay 5, 2024 | finance.yahoo.comEarnings Beat: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsMay 4, 2024 | finance.yahoo.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2024 Earnings Call TranscriptMay 3, 2024 | marketbeat.comAgios Pharmaceuticals (NASDAQ:AGIO) Posts Quarterly Earnings Results, Beats Expectations By $0.19 EPSAgios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.64) by $0.19. The business had revenue of $8.19 million during the quarter, compared to the consensus estimate of $8.37 million. Agios Pharmaceuticals had a negative net margin of 1,312.64% and a negative return on equity of 38.08%. Agios Pharmaceuticals's quarterly revenue was up 46.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.47) EPS.May 3, 2024 | marketbeat.comThe Goldman Sachs Group Increases Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $33.00The Goldman Sachs Group increased their price target on shares of Agios Pharmaceuticals from $29.00 to $33.00 and gave the stock a "neutral" rating in a research report on Friday.May 3, 2024 | finance.yahoo.comAgios Pharmaceuticals First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 3, 2024 | globenewswire.comAgios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024May 3, 2024 | finance.yahoo.comQ1 2024 Agios Pharmaceuticals Inc Earnings CallMay 2, 2024 | seekingalpha.comAgios Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 2, 2024 | investorplace.comAGIO Stock Earnings: Agios Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024 Get Agios Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Secret energy grid to power millions of homes (Ad)This high-security, secret U.S. facility has 2,100 engineers, machinists, and technicians building a new type of energy system the world has never seen before. Click here to get all the details. AGIO Media Mentions By Week AGIO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AGIO News Sentiment▼0.620.73▲Average Medical News Sentiment AGIO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AGIO Articles This Week▼294▲AGIO Articles Average Week Get Agios Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Insmed News Ascendis Pharma A/S News Cerevel Therapeutics News Legend Biotech News Intra-Cellular Therapies News Viking Therapeutics News Jazz Pharmaceuticals News Blueprint Medicines News Summit Therapeutics News Organon & Co. News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AGIO) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | Sponsored